Indeed, our data suggest that its loss may significantly mitigate disease risk by reducing the expression of several proteins (ESRP1 and DHRS2) with known deleterious effects in endometrial cancer (Supplementary Table 3) in addition to modulating cell viability and proliferative capacity. This evidence concerns the gene DHRS2 and endometrial cancer.